Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant monilial infection

A technology of targeted therapy and cinnamaldehyde, applied in the field of medicine, can solve the problems of poor prognosis and difficult clinical treatment.

Active Publication Date: 2017-01-25
THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the above-mentioned drugs have certain antibacterial effects, due to the increasing number of drug-resistant strains in recent years, especially resistant to azole drugs, such as fluconazole, itraconazole, voriconazole, ketoconazole, and flucytosine, Amphotericin B, etc., clinical treatment is still relatively difficult, and the prognosis is poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant monilial infection
  • Application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant monilial infection
  • Application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant monilial infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0043] Embodiment 2 Cinnamaldehyde monomer clathrate of the present invention

[0044] Composition: Cinnamaldehyde 1.25g (50 parts by weight)

[0045] 2-hydroxypropyl-β-cyclodextrin 1.25g (50 parts by weight)

[0046] Preparation:

[0047] 1) Add 2-hydroxypropyl-β-cyclodextrin into deionized distilled water at 90°C, stir to dissolve, then cool down to 20°C to prepare an aqueous solution for later use; among them, 2-hydroxypropyl-β-cyclodextrin The weight mg / volume mL ratio of essence and deionized distilled water is 1:8;

[0048] 2) Under stirring, slowly add cinnamon aldehyde dissolved in ethyl acetate dropwise to the aqueous solution obtained in step 1). After the dropwise addition, raise the temperature to 70°C and continue stirring for 1 hour, then refrigerate for 24 hours to obtain a refrigerated solution , standby; wherein, the volume mL ratio of cinnamaldehyde to ethyl acetate is 1:6;

[0049] 3) Filter the refrigerated liquid obtained in step 2), wash the solid mat...

Embodiment 3

[0050] Embodiment 3 Cinnamaldehyde monomer clathrate of the present invention

[0051] Composition: Cinnamaldehyde 1g (10 parts by weight)

[0052] 2-hydroxypropyl-β-cyclodextrin 2g (20 parts by weight)

[0053] Preparation method: with embodiment 2.

Embodiment 4

[0054] Embodiment 4 Cinnamaldehyde monomer clathrate of the present invention

[0055] Composition: Cinnamaldehyde 6g (60 parts by weight)

[0056] 2-hydroxypropyl-β-cyclodextrin 8g (80 parts by weight)

[0057] Preparation method: with embodiment 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant monilial infection, and belongs to the technical field of medicines. Drug-resistant monilia is invasive and disseminative drug-resistant monilia such as monilia albicans, candida krusei, candida glabrata or candida parapsilosis. A cinnamaldehyde inclusion compound preparation is developed by methods of tissue mycology, tissue pathology, tissue biochemistry and tissue electron microscopy. An efficient, low-toxicity and novel antibacterial agent which is used for targeted therapy of drug-resistant monilial infection is provided for fungal infection of departments such as a clinical pneumology department, a hematology department, an emergency treatment ICU, an oncology department and organ grafting, in-vivo pharmacodynamics, an action mechanism and a theoretical experiment basis are provided for research and development of traditional Chinese medicines for treating invasive and disseminative drug-resistant monilial infection, and conditions are created for transformation of scientific achievements.

Description

technical field [0001] The invention relates to the application of an active ingredient in the preparation of medicines, more specifically, relates to the application of cinnamaldehyde in the preparation of medicines for targeted treatment of drug-resistant Candida infection, and belongs to the technical field of medicine. Background technique [0002] Invasive disseminated drug-resistant fungal infection refers to fungal invasion of human tissues and blood, where they grow and reproduce, causing tissue damage, organ dysfunction, pathological changes and pathophysiological processes of inflammatory response. In recent years, with the continuous promotion and development of organ transplantation and various catheter technologies, the irrational use of antibiotics, and the number of critically ill patients treated with ventilator-assisted ventilation and parenteral nutrition support, the number of critically ill patients has continued to increase, coupled with changes in the sp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/11A61K47/69A61K47/26A61P31/10
CPCA61K31/11A61K47/26
Inventor 王刚生邓洁华李继红张朝军赵宜乐
Owner THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com